Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07464886 · ClinicalTrials.gov registry record · Phase 3
Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth
A Phase 3 study of Mild Depression, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT07464886: Recruiting Phase 3 study of Mild Depression, sponsored by University of Cincinnati.
NCT07464886 is a Phase 3 study of Mild Depression that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 160 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07464886, a Phase 3 study of Mild Depression, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.
Primary Outcome
Changes in glutamate levels, measured by proton spectroscopy, in the left VLPFC following 8-week treatment with NAC and/or MBCT.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG N-acetylcysteine
- BEHAVIORAL Mindfulness-based cognitive therapy
- BEHAVIORAL Sham mindfulness-based intervention
Study Locations (1)
Ohio
- University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-02-26 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
What NCT07464886 shows while recruiting
NCT07464886 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Mild Depression appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07464886 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07464886 about?
NCT07464886 is a clinical study titled "Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth". The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.
What is the current status of trial NCT07464886?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2026-02-26. Estimated completion is 2030-12.
What conditions does trial NCT07464886 study?
This clinical trial studies the following conditions: Mild Depression.
What interventions are being tested in trial NCT07464886?
The interventions under investigation include: Placebo (DRUG), N-acetylcysteine (DRUG), Mindfulness-based cognitive therapy (BEHAVIORAL), Sham mindfulness-based intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT07464886?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07464886 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07464886's enrollment target sits among peer trials
160 1480th of 2000 higher than 500 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI